Stability data of extemporaneous oral suspension of pentobarbital in Syrspend SF Alka for imaging sedation procedure

Benjamin Querin\textsuperscript{a}, Arnaud Schweitzer-Chaput\textsuperscript{a}, Chahrazed Nedjar\textsuperscript{a}, Joël Schlatter\textsuperscript{b,∗}

\textsuperscript{a} Hôpital universitaire Necker – Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), 149 rue de Sèvres, Paris, France
\textsuperscript{b} Hôpital Paul-Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 1 rue de l’hôpital, Liancourt, France

\textbf{ARTICLE INFO}

\textbf{Article history:}
Received 7 January 2021
Revised 10 February 2021
Accepted 12 February 2021
Available online 17 February 2021

\textbf{Keywords:}
Pentobarbital sodium
Pediatric
Sedation
Imaging
Stability
Oral suspension

\textbf{ABSTRACT}

Pentobarbital is used as an alternative in pediatric sedative imaging procedures. Pentobarbital is only available as pharmaceutical powder. Regardless of its clinical use, its manipulation is necessary by hospital pharmacists that must prepare adapted dosage forms for pediatrics. The data presented in this article suggest that extemporaneous suspensions of sodium pentobarbital in oral liquid base are stable for at least 120 days.

© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

\textbf{Specifications Table}

| Subject                  | Pharmacology, Pharmaceutical Science, Pediatrics |
|--------------------------|--------------------------------------------------|
| Specific subject area    | Pharmaceutical Science                           |
| Type of data             | Table                                             |
|                          | Figure                                           |
|                          | Text                                             |

(continued on next page)

\textsuperscript{∗} Corresponding author.

\textit{E-mail address: joel.schlatter@aphp.fr} (J. Schlatter).

https://doi.org/10.1016/j.dib.2021.106884
2352-3409/© 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
How data were acquired | High-Performance Liquid Chromatography (HPLC)
---|---
Data format | Raw
Parameters for data collection | Data on pentobarbital sodium stability in suspension through 120 days from preparation after storage at 5 ± 3 °C and 25 ± 3 °C
Description of data collection | The suspensions were prepared from pharmaceutical sodium pentobarbital powder using commercial Syrspend SF Alka vehicle. The suspensions were stored at 5 ± 3 °C and 25 ± 3 °C for 120 days and at scheduled times the samples were collected and analysed by HPLC.
Data source location | Paris, France
Data accessibility | Analysed data with the article. Additional tables and figures with supplementary data.

http://dx.doi.org/10.17632/2bh8fmt97y.2

Value of the Data

- The data support evidence on the pentobarbital chemical stability when the drug powder is suspended in Syrspend SF Alka reconstituted vehicle and stored for 120 days at two temperatures.
- The data enables hospital pharmacists and clinicians to use pentobarbital in a form suitable for pediatric radiology that addresses the absence of commercially available forms.
- The data reported in this study constitute a basis for further investigations to develop new formulations dedicated for pediatric patients for whom an oral liquid preparation is more suitable.

1. Data Description

Pentobarbital is a psychoactive drug with short-acting sedative effects in adult and pediatric patients. However, it is no longer marketed in Europe and in the United States, only the intravenous formulation of pentobarbital is available. Pentobarbital is used orally or rectally as an alternative in pediatric sedative procedures such as computed tomography or magnetic resonance imaging in infants to control pain, anxiety, and mobility [1–5]. Some information on the drug stability has been reported referring to the degradation of the drug under acidic conditions [6–8]. With respect to the necessity to have a pH upper 8.0 to protect pentobarbital degradation, an oral liquid preparation with a basic pH consisted of producing a stable oral suspension in Syrspend SF Alka vehicle buffered at a pH >7. Analytical results showed that pentobarbital content of the suspension remained at least > 95% for 120 days under both conditions, suggesting minimal or no loss of drug due by degradation or absorption (Table 1). No detectable change in odor, taste, color, or visible microbial growth was observed in any of the samples. In the suspension stored at room temperature and refrigerated, the final pH values on day 120 changed statistically from the initial pH (Table 1). The pH value of the drug suspension was above 9 during the 120-day study period, as recommended in Borodkin et al. [9]. This stability study responded to the proposal by Schlatter et al. to formulate a pentobarbital flavoring and sweetening suspension at pH >9 [8].

2. Experimental Design, Materials and Methods

2.1. Materials

Pharmaceutical sodium pentobarbital powder (Ph. Eur.) obtained from Inresa Pharma (Bartenheim, France, lot 10,026/1111B479). Syrspend SF Alka purchased from Fagron (Rotterdam, Netherlands, lot 14/01-B03–300,337). This vehicle is a pre-measured alkaline suspending base for reconstitution and packaged in a graduated container allowing for compounding process directly
| Storage | Mean ± S.D. initial concentration (mg/mL) | Mean ± S.D.% initial concentration remaining |
|---------|------------------------------------------|---------------------------------------------|
|         |                                          | Day 7    | Day 14  | Day 21  | Day 30  | Day 45  | Day 60  | Day 90  | Day 120 |
| 22–25 °C| 25.18 ± 0.79                             | 97.89 ± 0.48 | 100.72 ± 0.67 | 102.20 ± 0.92 | 100.93 ± 1.14 | 98.93 ± 1.01 | 101.62 ± 0.44 | 98.78 ± 1.74 | 98.70 ± 0.95 |
| pH      | 9.92 ± 0.01                              | 99.77 ± 0.83 | 99.42 ± 0.63 | 99.93 ± 0.98 | 102.57 ± 1.43 | 101.08 ± 0.91 | 101.02 ± 0.43 | 99.25 ± 1.39 | 99.50 ± 1.22 |
| 4–8 °C  | 25.30 ± 0.78                             | 99.77 ± 0.83 | 99.42 ± 0.63 | 99.93 ± 0.98 | 102.57 ± 1.43 | 101.08 ± 0.91 | 101.02 ± 0.43 | 99.25 ± 1.39 | 99.50 ± 1.22 |
| pH      | 9.92 ± 0.01                              | 10.02 ± 0.01| 99.50 ± 1.22 | 10.02 ± 0.01| 99.50 ± 1.22 | 10.02 ± 0.01| 99.50 ± 1.22 | 10.02 ± 0.01| 99.50 ± 1.22 |

* p < 0.0001 (t-test comparing the means of initial and final pH).
into the dispersing container. Syrprend SF Alka is free of sugars and preservatives. It consists of calcium carbonate, modified food starch, and sucralose. It has low osmolality (<50 mOsmol/kg) and is specifically designed for acid-labile drugs. Purified water obtained from Fresenius Kabi (Versylène, Sèvres, France). All other chemicals and solvents used in this study were analytical grade.

2.2. Suspension preparation

Oral suspension of sodium pentobarbital 25 mg/mL was prepared by exactly weighed 2500-mg active pharmaceutical sodium pentobarbital powder and transferred into a mortar to obtain a fine and homogenous powder. The powder was transferred to the original container of vehicle and mixed. The mixed powder was then reconstituted with purified water to the final volume of 100 mL. The suspension was thoroughly mixed to obtain a uniform suspension. The method for suspension preparation was based on the general protocol indicated by the vehicle manufacturer. Three identical samples of the formulation were prepared in the original vehicle container with a safety cap and stored at room temperature (25 ± 3 °C) and at refrigerated temperature (5 ± 3 °C).

2.3. Stability study

Following resuspension by shaking, aliquots of suspension from each of the stored samples were extracted on days 0, 7, 14, 21, 30, 45, 60, 90, and 120. After shaking by hand to prevent foaming, 1 mL of collected sample was diluted in 250 mL of purified water and was mixed for 10 s using a vortex before being analysed by HPLC. This method was reproduced from the previous publication of Schlatter et al. Stability was defined as retention of at least 90% of the initial drug concentration. All experiments were performed in triplicate.

2.4. Stability-indicating HPLC method

Pentobarbital concentration was measured using a previously published high-performance liquid chromatography (HPLC) stability-indicating method. HPLC system (Dionex Ultimate 3000, Thermo Scientific, Villebon-sur-Yvette, France) was used with HPG-3200SD quaternary pump, WPS-3000TSL autosampler, and MWD-3000 variable wavelength detector. Data acquisition was carried out using in line Chromelgon® software (v6.80 SP2, Thermo Scientific). Chromatographic separation was achieved at 25 °C using a Nova-Pak (4 μm, 4.6 × 150 mm) C18 column (Waters, Guyancourt, France). The elution was run isocratically with a mobile phase consisting of 0.01 M potassium buffer pH 3 (400 mL) and methanol (600 mL) at a flow rate of 1.0 mL/min. The HPLC limit of detection was set at 214 nm. Chromatogram of pentobarbital in suspension is described in Fig. 1. Briefly, standard solution of pentobarbital sodium was prepared by accurately weighing 100 mg and diluted them with purified water to a final concentration of 0.1 mg/mL. Appropriate volumes of standard solution were diluted with purified water to yield 5 to 200 μg/mL for linearity. The injection volume was set at 25 μL.

2.5. Validation parameters of the HPLC method

The method was validated according to the International Council for harmonisation (ICH) Q2(R1) guidelines. A stock solution of sodium pentobarbital (1 mg/mL) was prepared by dissolving the bulk drug in purified water. The linearity of the method was demonstrated using six different concentrations of pentobarbital sodium in a range between 50 and 200 μg/mL with R² > 0.999 (Fig. 2, Table S3). Each concentration peak area was recorded in triplicate, and taken average area from triplicate injections. The lower limit of detection (LOD) and lower limit of
quantification (LOQ) for pentobarbital was evaluated on standard deviation of the response and the slope of the calibration curve. LOD and LOQ were 1.5 mg/mL and 4.6 mg/mL, respectively. The percent relative standard deviation (%RSD) ranged from 1.2% to 2.5% at 50 μg/mL 0.9% to 1.1% at 150 μg/mL over the 3 separate days. The overall %RSD was less than 3% for all 3 days. To demonstrate the ability of the assay to be stability indicating, pentobarbital was subjected to acidic (12 N HCl), alkaline (10 N NaOH), and oxidative (3% H₂O₂) stress conditions for 48 h at 50 °C. Fig. 3 shows the chromatograms demonstrating the stability-indicating method. In these strong stress conditions, more than 50% loss of pentobarbital was observed in acidic and oxidative stress conditions, while loss due to alkaline stress condition was less than 10%.

2.6. Physical stability

The pH variations were determined in the stability study on day 0 and day 120 with a calibrated pH meter (SevenExcellence digital pH meter, Mettler-Toledo, Viroflay, France). Samples were also observed for any visual change on each day analysis against black and white
Fig. 3. High-performance liquid chromatograms from forced degradation study.

backgrounds. A statistical parametric t-test was used to compare the means of the pH using the software Prism 6 (Version 6.01, GraphPad Software, San Diego, USA).

Ethics Statement

Not applicable.

CRediT Author Statement

Joël Schlatter: Conceptualization, Methodology, Writing, Reviewing and Editing; Benjamin Querin: Data curation, Investigation; Arnaud Schweitzer-Chaput: Data curation, Formal analysis, Investigation; Chahrazed Nedjar: Software, Validation.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships which have, or could be perceived to have, influenced the work reported in this article.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Supplementary Materials

Supplementary materials associated with this article can be found in the online version at doi: 10.17632/2bh8fmt97y.2.
References

[1] V.E. Karian, P.E. Burrows, D. Zurakowski, L. Connor, K.P. Mason, Sedation for pediatric radiological procedures: analysis of potential causes of sedation failure and paradoxical reactions, Pediatr. Radiol. 29 (1999) 869–873, doi:10.1007/s002470050715.

[2] K.L. Napoli, G.G. Ingall, G.R. Martin, Safety and efficacy of chloral hydrate sedation in children undergoing echocardiography, J. Pediatr. 129 (1996) 287–291, doi:10.1016/s0022-3476(96)70256-1.

[3] S.B. Greenberg, E.N. Faerber, C.L. Aspinall, R.C. Adams, High-dose chloral hydrate sedation for children undergoing MR imaging: safety and efficacy in relation to age, Am. J. Roentgenol. Radium Ther. Nucl. Med. 161 (1993) 639–641, doi:10.2214/ajr.161.3.8352124.

[4] A. Chiaretti, F. Benini, F. Pierri, K. Vecchiato, L. Ronfani, C. Agosto, A. Ventura, O. Genovese, E. Barbi, Safety and efficacy of propofol administered by paediatricians during procedural sedation in children, Acta Paediatr. 103 (2014) 182–187, doi:10.1111/apa.12472.

[5] M. Alexander, Managing patient stress in pediatric radiology, Radiol. Technol. 83 (2012) 549–560.

[6] V.D. Gupta, Stability of pentobarbital sodium after reconstitution in 0.9% sodium chloride injection and repackaging in glass and polypropylene syringes, Int. J. Pharm. Compd. 5 (2001) 482–484.

[7] S.M. Priest, T.P. Geisbuhler, Injectable sodium pentobarbital: stability at room temperature, J. Pharmacol. Toxicol. Methods 31 (2005) 38–42, doi:10.1016/j.vascn.2015.07.012.

[8] J. Schlatter, S. Kabiche, I.B. Balde, E. Majoul, S. Cisternino, J.F. Fontan, Stability of pentobarbital in water and oral pediatric suspensions, Ann. Pharmacother. 50 (2016) 245–246, doi:10.1177/1060028015625655.

[9] S. Borodkin, L. Macy, G. Thompson, R. Schmits, Stable nonaqueous pentobarbital sodium solutions for use in laboratory animals, J. Pharm. Sci. 66 (1977) 693–695, doi:10.1002/jps.2600660521.

[10] H.C. Polonini, S.L. Silva, S. Loures, R. Almy, A. Ballard, M.A.F. Brandão, A.O. Ferreira, Compatibility of proton pump inhibitors in a preservative-free suspending vehicle, Eur. J. Hosp. Pharm. 25 (2018) 150–156, doi:10.1136/ejhipharm-2016-001034.

[11] J. Schlatter, S. Kabiche, N. Sellier, J.E. Fontan, Oral pentobarbital suspension for children sedation during MR imaging, Ann. Pharm. Fr. 76 (2018) 286–290, doi:10.1016/j.pharma.2018.03.002.

[12] M. Ajemni, I.B. Balde, S. Kabiche, S. Carret, J.E. Fontan, S. Cisternino, J. Schlatter, Stability-indicating assay for the determination of pentobarbital sodium in liquid formulations, Int. J. Anal. Chem. 2015 (2015) 697937, doi:10.1155/2015/697937.

[13] European Medicines Agency. ICH Topic Q1A(R2): stability testing of new drug substances and products. www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-products-step-5_en.pdf, [Accessed: 08 February 2021].